

Sexual Dysfunction and Quality of Life after Treatment for Localized Prostate Cancer: The Role of Sexual Desire and Bother

Catherine Benedict, M.S.
University of Miami

This study was supported by a center grant from the
National Cancer Institute (1P50CA84944 and U01CA861)

Frank J. Penedo, Ph.D.

Prostate Cancer (PC)


- Most common non-skin cancer among U.S. men
 - Over 220,000 new diagnoses in 2011
 - Over 2.2 million current survivors
- Diagnosed in early stages for the majority of men and standard treatment options include radical prostatectomy (RP) and radiation therapy (RT)
 - 5- and 10-year survival rates are 100% and 93%, respectively

Prostate Cancer (PC)

- Survivorship is often affected by long-standing, disease- and treatment-related side effects that **challenge quality of life (QoL)**
- **Sexual side effects** are particularly distressing
- Declines in sexual functioning have been shown to be **more severe than age-related morbidity** and are experienced **across treatment types**

Sexual Side Effects


Compared to Matched Controls



*Measured using the UCLA – Prostate Cancer Index (UCLA – PCI; Litwin et al. 1998; Hoffman et al., 2004)

Sexual Side Effects

Across Treatment Types



*Measured using the UCLA – Prostate Cancer Index (UCLA – PC; Litwin et al. 1998; Potosky et al., 2000; 2004)


Sexual Side Effects

- Generally associated with **compromised QOL**
 - Increased distress, depression, and anxiety
 - Body image and masculinity
 - Self-esteem
 - Quality of marital/partner relationships
- However, typically assessed using measures that primarily focus on **physiologic impairment**
 - Erectile dysfunction
- Impact of other domains of **sexuality** on QOL have rarely been considered

(e.g., Beck et al., 2007; Boehmer & Babayan, 2004; Bokhour et al., 2001; Chambers, 2008; Howlett et al., 2010; Nelson, Choi, Mulhali, & Roth, 2007)

Sexuality

■ Multidimensional construct



Sexuality

- Although PC treatment often leads to decrements in multiple facets of sexuality
 - Erectile dysfunction / impotence
 - Loss of sexual desire
 - Problems with orgasms
 - Overall sexual dissatisfaction

Sexuality


- There is **variability** in the extent to which men are bothered or distressed by side effects
 - Not all men who experience dysfunction are bothered by it
 - Measures of dysfunction and bother often uncorrelated
- For some men, overall adjustment and well being may be independent of recovery of function
- Important to consider different dimensions of sexuality independently in determining effects on QOL

Sexuality

- Although sexual side effects are generally associated with worse QOL
- Most studies have focused on **sexual dysfunction** (i.e., physiologic impairment)
- Independent effects of other facets of sexuality, such as **sexual desire** and **bother**, have rarely been considered


Dysfunction, Desire, and Bother

- It is largely unknown how **sexual desire** and **bother** impact QOL among post-treatment PC patients, controlling for the effects of **sexual dysfunction**




Dysfunction, Desire, and Bother

- Furthermore, unknown how socio-demographic and health-related characteristics relate to different aspects of sexuality
- Implications for more general QOL?




Present Study

- Evaluated the direct and indirect effects on QOL




Present Study

1. Direct effects of **sexual desire** and **bother** on QOL would be significant, above and beyond the effects of **sexual dysfunction**



Present Study

2. Indirect effects of baseline characteristics on QOL, through sexual outcomes, would be significant
 - Risk factors associated with decrements in both sexuality and QOL would be identified



Present Study

- Participants were part of a larger NCI-funded study that evaluated the effects of a psychosocial intervention on QOL
 - Data from baseline assessment visit (2 weeks prior to the start of the intervention)
- Inclusion criteria
 - Age 50 or older
 - Undergone treatment for localized PC within the past 18 months
 - At least a 9th grade reading level
- Exclusion criteria
 - Prior history of any non-skin cancer
 - Significant cognitive impairment
 - Active psychiatric symptoms within the past 3 months
 - E.g., posttraumatic stress disorder, psychosis, or alcohol/drug dependence

Measures

- Socio-demographic and health-related covariates
 - Age
 - Ethnicity
 - Education
 - Employment status
 - Household income
 - Medical comorbidities
- PC-related covariates
 - Type of treatment (RP or RT)
 - Time since diagnoses
 - Time since treatment completion

Measures

- Socio-demographic and health-related covariates
 - Current relationship status (yes/no)
 - Ongoing sexual relationship prior to PC diagnosis (yes/no)
 - Pre-treatment sexual functioning (i.e., frequency of sexual activity; times per month)

Measures

- Sexual outcomes
 - UCLA-Prostate Cancer Index (UCLA) for post-RP participants
 - Expanded Prostate Cancer Index Composite (EPIC) for post-RT participants
 - **Sexual dysfunction** = physiologic impairment
 - Measured using a composite score of 7 items
 - Sample items:
 - “How would you rate the usual quality of your erections?”
 - Higher scores indicate *more* sexual dysfunction
 - Recoded from original scale

Measures

- Sexual outcomes
 - UCLA-Prostate Cancer Index (UCLA) for post-RP participants
 - Expanded Prostate Cancer Index Composite (EPIC) for post-RT participants
 - **Sexual desire**
 - Measured using a single item
 - “How would you rate your level of sexual desire during the past four weeks?”
 - 5-point response scale: “0 – Very poor” to “4 – Very good”
 - Higher scores indicate *more* desire

Measures


- Sexual outcomes
 - UCLA-Prostate Cancer Index (UCLA) for post-RP participants
 - Expanded Prostate Cancer Index Composite (EPIC) for post-RT participants
 - **Sexual bother**
 - Measured using a single item
 - “Overall, how big a problem has your sexual function been for you during the last 4 weeks?”
 - 5-point response scale: “0 – No problem” to “4 – Big problem.”
 - Higher scores indicate *more* bother

Measures

- QOL
 - Functional Assessment of Cancer – General Module (FACT – G)
 - Measures physical, social/family, emotional, and functional domains of QOL
 - A single item that measures current sexual satisfaction was removed to avoid overlap with other variables in the model
 - A total score was calculated from the remaining 26 items
 - 5-point response scale: “1 – Not at all” to “5 – Very much”
 - Higher scores indicated *better* QOL

Statistical Analyses


- All variables tested for normality
- Covariates included based on theory and prior findings



¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Statistical Analyses

- Structural equation modeling
 - Full information maximum likelihood (FIML) approach was used to generate parameter estimates




¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Statistical Analyses

■ Structural equation modeling

■ Model fit indices

- Chi-square statistic (χ^2 p-value >.05); comparative fit index (CFI >.95); standardized root mean square residual (SRMR <.08); root mean square error of approximation (RMSEA <.06)



¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group; Kline, 2005

Results

- Participants (N = 260)
 - Age: 65 years (SD = 7.6)
 - Ethnically diverse
 - 41% Non-Hispanic White, 17% African American/Black, 42% Hispanic
 - Education: 13.8 (SD = 3.4)
 - Income: \$51,000 (SD = \$50,000)
 - Average of 2 comorbid medical conditions
 - 17% reported diabetes
 - 14% reported cardiovascular disease

Results

- Participants (N = 260)
 - Treatment: 47% RP and 53% RT
 - 16 months (SD = 6.9) post-diagnosis
 - 10 months (SD = 4.5) post-treatment

Results

- Participants
 - 75% were married or in an equivalent relationship
 - 81% reported to have been in an ongoing sexual relationship prior to PC diagnosis

Results

- Sexual dysfunction
 - Mean = 6.06 (SD=6.1); range of 0–22
- Sexual desire
 - Average response between “poor” to “fair”
- Sexual bother
 - Average response between “small problem” to “moderate problem”


Results

- Quality of life
 - Mean = 85.2 (SD = 13.6)
 - Below average levels of QOL compared to published means
 - Localized PC (RP and RT Means = 92.4 and 90.2, respectively)
 - Age-matched control populations (Mean = 87.1)

Results

- Model fit the data


χ^2 *p*-value = .14; CFI = .99; SRMR = .01; RMSEA = .05



¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Results

- All sexual outcomes were significantly related




* $p < .05$; ** $p < .01$; † $p < .001$

¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Results


- More years of education, higher income, and fewer medical comorbidities related to higher levels of QOL



¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Direct Effects


- Sexual desire and bother were significantly related to QOL, but not sexual dysfunction



¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Indirect Effects

- Ethnicity → Sexual Bother → QOL
 - Hispanic ethnic identification was related to more sexual bother and lower levels of QOL (indirect effect; $\beta = -.04$, $p = .05$)




* $p < .05$; ** $p < .01$; † $p < .001$

¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Indirect Effects

- Type of treatment → Sexual Bother → QOL
 - RP associated with more sexual bother and lower levels of QOL (indirect effect; $\beta=.08, p<.01$)




* $p<.05$; ** $p<.01$; † $p<.001$

¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Indirect Effects

- Pre-treatment sexual function → Sexual Bother → QOL
 - Better pre-treatment sexual functioning associated with more sexual bother and lower levels of QOL (indirect effect; $\beta = -.06, p < .01$)



* $p < .05$; ** $p < .01$; † $p < .001$

¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Summary of Findings

- Although it is widely reported that sexual side effects have a negative impact on QOL, the impact of different domains of sexuality have rarely been considered
- Degree to which men perceive their sexual side effects as being a problem may be a more significant predictor of QOL than the level of physiologic impairment
 - Hispanic men
 - RP patients
 - High levels of pre-treatment sexual functioning

Implications

- The majority of men will never fully recover pre-treatment levels of sexual functioning
 - Even with the use of assistive aids and/or medical interventions
- Psychological processes related to sexual dysfunction may be more clinically relevant targets of intervention to ultimately improve QOL
 - Maladaptive cognitions related to perceived loss of masculinity
 - Performance anxiety associated with sexual intimacy

Limitations & Future Directions

- Cross-sectional design precludes causal inferences
 - Although sexual bother conceptualized as a mediating factor, time precedence could not be established
- Sexual desire and bother were each assessed using single items

Limitations & Future Directions

- Longitudinal relationships
- Psychosocial interventions among PC survivors
 - Target the effects of treatment on factors that relate to sexual desire and bother, in particular, and maladaptive perceptions of sexual dysfunction
 - Consider risk factors related to sexual bother and QOL
 - Ethnicity
 - Type of treatment
 - Pre-treatment level of sexual functioning

Contributors

Frank J. Penedo

Lara Traeger

Mikal Rasheed

Eric Zhou

Natalie Bustillo

Bruce Kava


Mark Soloway

**Center for Psycho-Oncology Research
Department of Psychology &
Sylvester Cancer Center**

University of Miami
Coral Gables, Florida


Present Study

- Evaluated the effects of sexual dysfunction, desire, and bother on QOL, controlling for relevant covariates




Present Study

- Determined whether baseline characteristics impacted sexual outcomes directly and whether there were subsequent indirect effects on general QOL



Statistical Analyses


- Model evaluated the main effects of sexual dysfunction, desire, and bother on QOL, while considering the effects of relevant covariates



¹Ethnicity included as two dummy coded variables; Non-Hispanic White reference group


Dysfunction, Desire, and Bother

- Furthermore, unknown how socio-demographic and health-related characteristics relate to different aspects of sexuality




Present Study

- Determined whether baseline socio-demographic and health-related characteristics were differentially related to different domains of sexuality




Present Study

- Direct effects of socio-demographic and health-related characteristics would vary across sexual outcomes



Direct Effects: Sexual Outcomes

- Older age and more medical comorbidities related to more sexual dysfunction




* $p < .05$; ** $p < .01$; † $p < .001$

¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Direct Effects: Sexual Outcomes

- RP patients reported more sexual dysfunction and more bother related to sexual side effects than RT patients




* $p < .05$; ** $p < .01$; † $p < .001$

¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Direct Effects: Sexual Outcomes

- Pre-treatment sexual functioning related to sexual bother ($\beta=.24, p<.01$)




* $p<.05$; ** $p<.01$; † $p<.001$

¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group

Direct Effects: Sexual Outcomes

- Hispanics reported lower levels of sexual desire ($\beta = -.15$, $p < .05$) and more sexual bother ($\beta = .14$, $p < .05$) compared to Non-Hispanic Whites



* $p < .05$; ** $p < .01$; † $p < .001$

¹Ethnicity included as two dummy coded variables with Non-Hispanic White as reference group; ²Type of treatment dummy coded with RP as reference group